Table 2 Prevalence of premature discontinuation of antiplatelets after ischemic stroke (n = 4621)
Variables | Discontinued < 6 months | Discontinued 6–12 months | Discontinued 12–18 months | Discontinued 18–24 months | Continued ≥24 months | ||||
|---|---|---|---|---|---|---|---|---|---|
| Â | All | Discontinued due to death | All | Discontinued due to death | All | Discontinued due to death | All | Discontinued due to death | Â |
| Â | Prevalence n (%) | Prevalence n (%) | Prevalence n (%) | Prevalence n (%) | Prevalence n (%) | Prevalence n (%) | Prevalence n (%) | Prevalence n (%) | Prevalence n (%) |
All antiplatelets (n = 4621) | 1170 (25.3%) | 103 (2.2%) | 470 (10.2%) | 114 (2.4%) | 369 (8.0%) | 97 (2.1%) | 695 (15.0%) | 85 (1.8%) | 1917 (41.5%) |
Aspirin (n = 1688) | 545 (32.3%) | 31 (1.8%) | 215 (12.7%) | 42 (2.5%) | 148 (8.8%) | 45 (2.7%) | 253 (15.0%) | 29 (1.7%) | 527 (31.2%) |
Clopidogerl (n = 2170) | 491 (22.6%) | 55 (2.5%) | 197 (9.1%) | 54 (2.5%) | 171 (7.9%) | 38 (1.8%) | 302 (13.9%) | 44 (2.0%) | 1009 (46.5%) |
Dual therapy (n = 763) | 134 (17.6%) | 17 (2.2%) | 58 (7.6%) | 18 (2.4%) | 50 (6.6%) | 14 (1.8%) | 140 (18.3%) | 12 (1.6%) | 381 (49.9%) |